4.13
+0.04(+0.98%)
Currency In USD
| Previous Close | 4.09 |
| Open | 4.09 |
| Day High | 4.14 |
| Day Low | 3.99 |
| 52-Week High | 7.55 |
| 52-Week Low | 2.12 |
| Volume | 1.13M |
| Average Volume | 4.69M |
| Market Cap | 410.14M |
| PE | -5.29 |
| EPS | -0.78 |
| Moving Average 50 Days | 3.95 |
| Moving Average 200 Days | 4.81 |
| Change | 0.04 |
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Mar 09, 2026 8:01 PM GMT
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science an
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science a